Holen Sie sich die Stockscreener-App
19.96
1.27%
0.25
Handel nachbörslich:
19.96
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Amphastar Pharmaceuticals (AMPH) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Challenging QuarterFull Year Guidance - newsline.com
(AMPH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Healthcare Stock Picks: RadNet and Amphastar to Sell, One Stock to Watch | June 2026News and Statistics - IndexBox
Amphastar Pharmaceuticals pivots to proprietary drugs, biosimilars for growth - MSN
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth - MarketBeat
How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts - Yahoo Finance
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged - GlobeNewswire
Amphastar Pharmaceuticals sees generic Atrovent fueling 2026 growth despite BAQSIMI drag - MSN
Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag - MarketBeat
Amphastar (AMPH) director awarded RSUs and options with tax withholding update - Stock Titan
Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant - Stock Titan
Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH) - Stock Titan
Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant - Stock Titan
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Amphastar (AMPH) holders approve directors, EY auditor and annual say-on-pay - Stock Titan
(AMPH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty - Yahoo Finance
Amphastar (AMPH) Q1 2026 Earnings Transcript - AOL.com
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference - ACCESS Newswire
(AMPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Amphastar Pharmaceuticals (AMPH) Shows Modest Gains as Stock Hovers Near Key ResistanceQuality Factor - The Legal Advocate
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19 - Insider Monkey
Amphastar Earnings Call Balances Growth and Margin Strain - TipRanks
Has Amphastar Pharmaceuticals Bottomed Out After Its Steep Decline - Kavout
8 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today - Yahoo Finance
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase - MSN
Amphastar Pharmaceuticals Q1 2026: Revenue Miss and Pricing Pressures on BAQSIMI - IndexBox
The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Pharma Earnings Season 2026: Amphastar Flat, Eli Lilly Surges in Q1News and Statistics - IndexBox
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment - Yahoo Finance
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings - simplywall.st
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
This Whirlpool Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $19 - Moomoo
Is Amphastar Pharmaceuticals Inc (AMPH) a Bargain After 5.6% Dro - GuruFocus
Amphastar Shares Fall After Wells Fargo Downgrade - Moomoo
Amphastar Pharmaceuticals tackles BAQSIMI discount pressure, keeps sales outlook - MSN
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook - MarketBeat
AMPH: Proprietary and biosimilar pipeline expansion drives growth, anchored by BAQSIMI® and Primatene MIST - TradingView
How The Amphastar Pharmaceuticals (AMPH) Narrative Is Shifting As Targets Fall And New Drugs Launch - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Neutral Rating from Piper Sandler - MarketBeat
(AMPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Amphastar price target lowered to $21 from $25 at Piper Sandler - TipRanks
Earnings Miss: Amphastar Pharmaceuticals, Inc. Missed EPS By 75% And Analysts Are Revising Their Forecasts - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narrative Despite Stable Revenue - Sahm
Needham downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Quarterly Earnings Results - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2026 Earnings Call Transcript - Insider Monkey
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):